Published in Biol Chem on May 01, 2008
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Cell-free protein synthesis: applications come of age. Biotechnol Adv (2011) 1.72
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
Vaccines: the fourth century. Clin Vaccine Immunol (2009) 1.61
Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol (2012) 1.58
A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J Immunol (2009) 1.50
Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway. PLoS One (2014) 1.45
Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv Mater (2011) 1.33
Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology. J Virol (2009) 1.28
Current progress in development of hepatitis C virus vaccines. Nat Med (2013) 1.28
Rationalizing the development of live attenuated virus vaccines. Nat Biotechnol (2010) 1.26
Norwalk virus-like particles as vaccines. Expert Rev Vaccines (2010) 1.23
Protein delivery using engineered virus-like particles. Proc Natl Acad Sci U S A (2011) 1.22
Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother (2012) 1.18
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr Opin Immunol (2010) 1.13
TLR signaling in B-cell development and activation. Cell Mol Immunol (2012) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins. J Virol (2010) 1.10
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Contribution of Toll-like receptor signaling to germinal center antibody responses. Immunol Rev (2012) 1.02
Proteinopathy-induced neuronal senescence: a hypothesis for brain failure in Alzheimer's and other neurodegenerative diseases. Alzheimers Res Ther (2009) 1.00
A virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol (2012) 0.99
Formulation of microneedles coated with influenza virus-like particle vaccine. AAPS PharmSciTech (2010) 0.98
Respiratory syncytial virus vaccine development. Clin Lab Med (2009) 0.98
Vaccine potential of Nipah virus-like particles. PLoS One (2011) 0.97
Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. Bioconjug Chem (2011) 0.95
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. Biomaterials (2013) 0.94
Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein. J Virol (2015) 0.93
Mining human antibody repertoires. MAbs (2010) 0.92
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Assembly and biological and immunological properties of Newcastle disease virus-like particles. J Virol (2010) 0.90
Guiding plant virus particles to integrin-displaying cells. Nanoscale (2012) 0.90
Multivalent display of proteins on viral nanoparticles using molecular recognition and chemical ligation strategies. Biomacromolecules (2011) 0.90
Virus-like particle-induced protection against MRSA pneumonia is dependent on IL-13 and enhancement of phagocyte function. Am J Pathol (2012) 0.90
Colorful virus-like particles: fluorescent protein packaging by the Qβ capsid. Biomacromolecules (2011) 0.89
Progress in respiratory virus vaccine development. Semin Respir Crit Care Med (2011) 0.89
A virus-like particle vaccine platform elicits heightened and hastened local lung mucosal antibody production after a single dose. Vaccine (2012) 0.89
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol (2012) 0.88
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
Using viruses as nanomedicines. Br J Pharmacol (2014) 0.86
Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res (2013) 0.83
Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One (2013) 0.83
A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA. PLoS One (2015) 0.82
HSV-1 amplicon vectors launch the production of heterologous rotavirus-like particles and induce rotavirus-specific immune responses in mice. Mol Ther (2012) 0.81
Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity. Biotechnol Bioeng (2015) 0.81
Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol (2009) 0.81
Induction of ebolavirus cross-species immunity using retrovirus-like particles bearing the Ebola virus glycoprotein lacking the mucin-like domain. Virol J (2012) 0.81
Non-carrier nanoparticles adjuvant modular protein vaccine in a particle-dependent manner. PLoS One (2015) 0.80
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
Newcastle disease virus-like particles: preparation, purification, quantification, and incorporation of foreign glycoproteins. Curr Protoc Microbiol (2013) 0.80
Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs. Adv Healthc Mater (2014) 0.80
Virus-based nanoparticles as platform technologies for modern vaccines. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2016) 0.80
Engineering virus-like particles as vaccine platforms. Curr Opin Virol (2016) 0.79
Computational tools for epitope vaccine design and evaluation. Curr Opin Virol (2015) 0.79
Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform. Curr Opin Virol (2015) 0.79
AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets (2009) 0.79
Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display. PLoS One (2015) 0.79
Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med (2015) 0.78
Presenting native-like trimeric HIV-1 antigens with self-assembling nanoparticles. Nat Commun (2016) 0.78
A vaccine of L2 epitope repeats fused with a modified IgG1 Fc induced cross-neutralizing antibodies and protective immunity against divergent human papillomavirus types. PLoS One (2014) 0.78
Max Bergmann lecture protein epitope mimetics in the age of structural vaccinology. J Pept Sci (2013) 0.78
T cells control the generation of nanomolar-affinity anti-glycan antibodies. J Clin Invest (2017) 0.78
Virus-like particle vaccine confers protection against a lethal newcastle disease virus challenge in chickens and allows a strategy of differentiating infected from vaccinated animals. Clin Vaccine Immunol (2014) 0.77
Chimeric infectious bursal disease virus-like particles as potent vaccines for eradication of established HPV-16 E7-dependent tumors. PLoS One (2012) 0.77
Nanotechnology for protein delivery: Overview and perspectives. J Control Release (2015) 0.77
Harnessing Nanoparticles for Immunomodulation and Vaccines. Vaccines (Basel) (2017) 0.76
Structural basis for the development of avian virus capsids that display influenza virus proteins and induce protective immunity. J Virol (2014) 0.76
Is The Allergen Really Needed in Allergy Immunotherapy? Curr Treat Options Allergy (2015) 0.76
Delivery strategies for novel vaccine formulations. World J Virol (2012) 0.76
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle Platform. PLoS One (2015) 0.76
Nanoassembly routes stimulate conflicting antibody quantity and quality for transmission-blocking malaria vaccines. Sci Rep (2017) 0.75
The germinal center antibody response in health and disease. F1000Res (2016) 0.75
Construction and characterization of recombinant human adenovirus type 5 expressing foot-and-mouth disease virus capsid proteins of Indian vaccine strain, O/IND/R2/75. Vet World (2015) 0.75
Secreted production of assembled Norovirus virus-like particles from Pichia pastoris. Microb Cell Fact (2014) 0.75
Differential Antibody Responses to Conserved HIV-1 Neutralizing Epitopes in the Context of Multivalent Scaffolds and Native-Like gp140 Trimers. MBio (2017) 0.75
Construction and characterization of insect cell-derived influenza VLP: cell binding, fusion, and EGFP incorporation. J Biomed Biotechnol (2010) 0.75
Rabbit hemorrhagic disease virus capsid, a versatile platform for foreign B-cell epitope display inducing protective humoral immune responses. Sci Rep (2016) 0.75
Newcastle disease virus-like particles induce dendritic cell maturation and enhance viral-specific immune response. Virus Genes (2017) 0.75
mTOR regulates memory CD8 T-cell differentiation. Nature (2009) 10.07
Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol (2005) 3.14
Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol (2008) 2.97
Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet (2008) 2.77
Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science (2007) 2.67
Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol (2004) 2.59
Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med (2002) 2.54
The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol (2004) 2.11
A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One (2008) 2.07
TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol (2007) 1.95
Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol (2006) 1.84
A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol (2005) 1.84
Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol (2006) 1.75
Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol (2004) 1.74
Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity (2011) 1.70
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens (2007) 1.68
CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity (2005) 1.63
Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol (2006) 1.59
VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest (2006) 1.51
A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine (2002) 1.48
Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol (2002) 1.39
Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol (2011) 1.37
Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov (2010) 1.36
Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity (2008) 1.34
Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A (2011) 1.33
Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol (2010) 1.32
Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol (2008) 1.30
Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol (2003) 1.26
Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A (2005) 1.21
Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A (2008) 1.14
A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol (2007) 1.13
Rapid response of marginal zone B cells to viral particles. J Immunol (2004) 1.13
Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol (2007) 1.12
Versatile virus-like particle carrier for epitope based vaccines. PLoS One (2010) 1.12
Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs (2007) 1.11
Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol (2010) 1.11
Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol (2006) 1.11
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol (2002) 1.10
Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol (2012) 1.09
Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol (2012) 1.09
Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol (2003) 1.09
Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol (2008) 1.07
Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol (2002) 1.07
Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol (2007) 1.06
Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol (2009) 1.05
Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine (2010) 1.05
Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother (2010) 1.04
Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med (2005) 1.04
The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci (2011) 1.03
Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med (2007) 1.03
A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J (2010) 1.03
Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol (2010) 1.01
Vaccination against GIP for the treatment of obesity. PLoS One (2008) 1.01
Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol (2005) 1.01
Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol (2012) 1.01
Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol (2002) 1.00
Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines (2008) 0.99
Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol (2009) 0.98
Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol (2005) 0.96
Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine (2010) 0.94
Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol (2010) 0.94
Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med (2009) 0.94
Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol (2005) 0.94
Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A (2009) 0.93
Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol (2004) 0.92
Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol (2008) 0.91
Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2. Thromb Haemost (2003) 0.91
Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol (2005) 0.90
Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J (2009) 0.90
Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol (2009) 0.90
Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines (2012) 0.88
Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol (2013) 0.88
CD36 is differentially expressed on B cell subsets during development and in responses to antigen. J Immunol (2008) 0.87
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol (2013) 0.86
IL-21 induces death of marginal zone B cells during chronic inflammation. Blood (2010) 0.86
Virus-like particles induce robust human T-helper cell responses. Eur J Immunol (2011) 0.85
Enhanced apoptotic activity of a structurally optimized form of galectin-1. Mol Immunol (2004) 0.85
Virus-like particles as a modular system for novel vaccines. Intervirology (2002) 0.85
Vaccines against non-communicable diseases. Curr Opin Immunol (2010) 0.84
Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One (2013) 0.83
Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A (2012) 0.81
Immunization against angiotensins for the treatment of hypertension. Clin Immunol (2009) 0.81
Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles. J Immunol (2009) 0.81
Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody. J Mol Biol (2011) 0.81
A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis. Eur J Immunol (2013) 0.80
Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology (2004) 0.80
CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol (2004) 0.80
Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther (2006) 0.79
Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy (2010) 0.79
T cell-dependent and -independent IgA responses: role of TLR signalling. Immunol Invest (2010) 0.79
Heterogeneous antibody repertoire of marginal zone B cells specific for virus-like particles. Microbes Infect (2007) 0.79
A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today (2006) 0.78
A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. J Immunol (2010) 0.78
Identification of Ly-6K as a novel marker for mouse plasma cells. Mol Immunol (2008) 0.77
Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands. Microbes Infect (2005) 0.77
Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther (2003) 0.76
Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol (2014) 0.76
Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One (2013) 0.76
Function of marginal zone B cells in antiviral B-cell responses. Crit Rev Immunol (2005) 0.76
Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG? Hum Vaccin (2010) 0.75